Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7033363
Reference Type
Journal Article
Title
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Author(s)
Feng, X; Sureda, A; Jafari, S; Memariani, Z; Tewari, D; Annunziata, G; Barrea, L; Hassan, STS; Šmejkal, K; Malaník, M; Sychrová, A; Barreca, D; Ziberna, L; Mahomoodally, MF; Zengin, G; Xu, S; Nabavi, SM; Shen, AZ; ,
Year
2019
Is Peer Reviewed?
1
Journal
Theranostics
ISSN:
1838-7640
Publisher
IVYSPRING INT PUBL
Location
LAKE HAVEN
Page Numbers
1923-1951
Language
English
PMID
31037148
DOI
10.7150/thno.30787
Web of Science Id
WOS:000461767700008
Abstract
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity